Additionally, in vivo tumourigenesis experiments in mice have demonstrated the role of S1PR2 as an oncogene in the onset and progression of NAFLD-HCC. This evidence concerns the gene S1PR2 and metabolic dysfunction-associated steatotic liver disease.